Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice

Roberto Castelli(University of Milan), Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), Antonino Cannavò(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), G. Grava(University of Milan), Fabio Conforti(Humanitas Gavazzeni)
Immunopharmacology and Immunotoxicology
March 9, 2012
10.3109/08923973.2012.658921
Cited by 18

Related Papers

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)
|Blood|2009|433
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial
|Journal of Clinical Oncology|2016|394
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients
|Blood|2014|373
Angiogenesis in myelodysplastic syndromes
|British Journal of Cancer|1999|272
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
|Leukemia|2018|250